CA2002182A1 - Compositions pour le traitement du syndrome premenstruel ou de la phase luteinique tardive, et leur mode d'emploi - Google Patents

Compositions pour le traitement du syndrome premenstruel ou de la phase luteinique tardive, et leur mode d'emploi

Info

Publication number
CA2002182A1
CA2002182A1 CA 2002182 CA2002182A CA2002182A1 CA 2002182 A1 CA2002182 A1 CA 2002182A1 CA 2002182 CA2002182 CA 2002182 CA 2002182 A CA2002182 A CA 2002182A CA 2002182 A1 CA2002182 A1 CA 2002182A1
Authority
CA
Canada
Prior art keywords
methods
compositions
premenstrual
treating
luteal phase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA 2002182
Other languages
English (en)
Other versions
CA2002182C (fr
Inventor
Richard J. Wurtman
Judith J. Wurtman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Priority to CA 2002182 priority Critical patent/CA2002182C/fr
Publication of CA2002182A1 publication Critical patent/CA2002182A1/fr
Application granted granted Critical
Publication of CA2002182C publication Critical patent/CA2002182C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA 2002182 1989-11-03 1989-11-03 Compositions pour le traitement du syndrome premenstruel ou de la phase luteinique tardive, et leur mode d'emploi Expired - Fee Related CA2002182C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA 2002182 CA2002182C (fr) 1989-11-03 1989-11-03 Compositions pour le traitement du syndrome premenstruel ou de la phase luteinique tardive, et leur mode d'emploi

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA 2002182 CA2002182C (fr) 1989-11-03 1989-11-03 Compositions pour le traitement du syndrome premenstruel ou de la phase luteinique tardive, et leur mode d'emploi

Publications (2)

Publication Number Publication Date
CA2002182A1 true CA2002182A1 (fr) 1991-05-03
CA2002182C CA2002182C (fr) 2000-06-13

Family

ID=4143458

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2002182 Expired - Fee Related CA2002182C (fr) 1989-11-03 1989-11-03 Compositions pour le traitement du syndrome premenstruel ou de la phase luteinique tardive, et leur mode d'emploi

Country Status (1)

Country Link
CA (1) CA2002182C (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006108591A1 (fr) 2005-04-11 2006-10-19 Novartis Ag 1h-quinaz0line-2,4-diones et leur utilisation en tant que ligands du recepteur ampa
EP2336129A1 (fr) 2004-06-18 2011-06-22 Novartis AG 1-aza-bicyclo[3.3.1]nonanes
EP2354141A1 (fr) 2005-12-16 2011-08-10 Novartis AG (1-aza-bicyclo[3.3.1]non-4-yl)-[5-(1h-indol-5-yl)-heteroaryl]-amines en tant que ligands cholinergiques du n-achr pour le traitement de troubles psychotiques et neurodegeneatifs
EP2361914A1 (fr) 2005-12-16 2011-08-31 Novartis AG [(1h-indol-5-yl)-heteroaryloxy]-(1-aza-bicyclo[3.3.1]nonanes comme ligands cholinergiques de n-achr pour le traitement des troubles psychotiques et neurodegeneratifs.
EP2457911A1 (fr) 2004-07-14 2012-05-30 Novartis AG Dérivés de 3-(hétéroaryl-oxy)-2-alkyl-1-aza-bicycloalkyle en tant que ligands nAChR alpha7 pour le traitement des maladies du SNC

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2336129A1 (fr) 2004-06-18 2011-06-22 Novartis AG 1-aza-bicyclo[3.3.1]nonanes
EP2457911A1 (fr) 2004-07-14 2012-05-30 Novartis AG Dérivés de 3-(hétéroaryl-oxy)-2-alkyl-1-aza-bicycloalkyle en tant que ligands nAChR alpha7 pour le traitement des maladies du SNC
WO2006108591A1 (fr) 2005-04-11 2006-10-19 Novartis Ag 1h-quinaz0line-2,4-diones et leur utilisation en tant que ligands du recepteur ampa
EP2463278A1 (fr) 2005-04-11 2012-06-13 Novartis AG 1h-quinaz0line-2,4-diones et leur utilisation en tant que ligands du recepteur ampa
EP2468732A1 (fr) 2005-04-11 2012-06-27 Novartis AG 1H-quinazoline-2,4-diones
EP2476671A1 (fr) 2005-04-11 2012-07-18 Novartis AG 1H-quinazoline-2,4-diones
EP2354141A1 (fr) 2005-12-16 2011-08-10 Novartis AG (1-aza-bicyclo[3.3.1]non-4-yl)-[5-(1h-indol-5-yl)-heteroaryl]-amines en tant que ligands cholinergiques du n-achr pour le traitement de troubles psychotiques et neurodegeneatifs
EP2361914A1 (fr) 2005-12-16 2011-08-31 Novartis AG [(1h-indol-5-yl)-heteroaryloxy]-(1-aza-bicyclo[3.3.1]nonanes comme ligands cholinergiques de n-achr pour le traitement des troubles psychotiques et neurodegeneratifs.

Also Published As

Publication number Publication date
CA2002182C (fr) 2000-06-13

Similar Documents

Publication Publication Date Title
CA2001572A1 (fr) Composes pour le traitement des symptomes de sevrage du tabac
MY106272A (en) Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants.
EP0419653A4 (en) Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
DE69202207D1 (de) Verfahren zur Herstellung von 1-Chlor-1,1,3,3,3-Pentafluorpropan und von 1,1,1,3,3,3-Hexafluorpropan.
IE893712L (en) Quinuclidines, their use as medicaments and processes for¹their preparation
IL96458A0 (en) Isoxazolines,their preparation,and their use as plantprotecting agents
AU5642294A (en) Bacteriocidal gas composition and process for preparing the same
DE3856295D1 (de) Behandlung des prämenstruellen oder späten lutealsphase-syndroms
RU93058535A (ru) Таблетка, содержащая гидрохлорид колестипола и способ ее получения
AU7239794A (en) Process for preparing 5,8-dihydronaphthoquinone derivatives, novel 5,8-dihydronaphthoquinone derivatives and their use as anticancer agent
LTIP1687A (en) Novel antiarrhythmic agents, process for the preparation thereof and pharmaceutical compositions
CA2002182A1 (fr) Compositions pour le traitement du syndrome premenstruel ou de la phase luteinique tardive, et leur mode d'emploi
GB8917687D0 (en) Aminopiperazine derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
PT66089B (en) Process for preparing 1,2-benzisothiazolin-3-ona with anti-thrombotic effect application of same for the preparationof pharmaceutical compositions with anti-thrombic effect and application of these pharmaceutical compositions for the treatment of thrombosis
ZA925892B (en) Organic nitrates, processes for their preparation and their use in the treatment of cardiovascular diseases.
EP0318233A3 (fr) Inhibiteurs d'assimilation de sérotonine et de norépinéphrine
EP0264744A3 (en) Process for the preparation of 4,4'-diaminodiphenylmethane and its derivatives.
LTIP911A (en) Indenoindole compounds i,process for preparing thereof,pharmaceutical compositions containing this compounds,and their use
AU4926190A (en) 2,3,23-trihydroxy-urs-12-ene and its derivatives, processes for their preparation and their use
CA2263846A1 (fr) Nouveaux derives de pyranoside
ZA906744B (en) Novel aminopropanol derivatives,process for their preparation and pharmaceutical compositions comprising the same
IL95210A0 (en) 14,17alpha-etheno-and-ethanoestratrienes,process for the preparation thereof and pharmaceutical compositions containing the same
CA2019745A1 (fr) Preparation pour le traitement et la prevention des thromboses et des complications thromboemboliques, utilisation d'une telle preparation et methode de production
EP0386920A3 (fr) Dérivés d'hydroxy-2-thiénylox-3-propylamine
HUT53773A (en) Antidotums containing substituted 1,8-naphtiridine derivatives as aktive components and process for producing the active components

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed